Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P910056/S062

enVista Hydrophobic Acrylic Intraocular Lens (IOL); enVista Hydrophobic Acrylic Intraocular Lens

Bausch + Lomb, Inc. · Decision date Jul 22, 2026

FDA DECISIONP910056/S062

What did the FDA decide?

FDA records P910056/S062 as a supplement to PMA P910056, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 22, 2026.

FDA approval order statement

a change to the Refractive Index Test Instrument (refractometer)
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Jul 22, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P910056/S062
Regulatory pathway
PMA supplement
Product code
HQL
Decision code
OK30
Decision date
Jul 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: intraocular lens.

Product code
HQL
FDA device class
3

For the original device and its historical approval scope, see PMA P910056. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P910056 · Original PMA

    SOFLEX UV-ABSORBING SILICONE POSTERIOR CHAMBER INTRAOCULAR LENS

  2. P910056/S062 received

    Application receipt date recorded by FDA.

  3. P910056/S062 · FDA decision

    30-Day Notice

  4. P910056/S063 · Related supplement

    enVista hydrophobic acrylic intraocular lens

  5. P910056/S065 · Related supplement

    enVista Aspire Hydrophobic Acrylic Intraocular Lens (IOL)

  6. P910056/S064 · Related supplement

    enVista Hydrophobic Acrylic Intraocular Lens

  7. P910056/S066 · Related supplement

    enVista Hydrophobic Acrylic Intraocular Lens

  8. P910056/S067 · Related supplement

    enVista Hydrophobic Acrylic Intraocular Lens

Timeline entries are records held by MedtechLedger for P910056. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P910056

Explore the linked device profile

Other records with product code HQL

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bausch + Lomb, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
50 Technology Dr., Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records